Indaptus Therapeutics Secures $6 Million Investment Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2025
0mins
Source: Globenewswire
Indaptus Therapeutics Inc. experienced a significant price increase of 9.93%, crossing above the 5-day SMA, despite the broader market's decline with the Nasdaq-100 down 0.32% and the S&P 500 down 0.29%.
This surge is attributed to the company's announcement of a $6 million securities purchase agreement with investor David E. Lazar, which includes the issuance of 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock. This investment is expected to bolster the company's capital base and support future strategic developments, alongside a leadership change with Lazar appointed as Co-CEO and Chairman of the Board.
The implications of this investment are significant, as it not only strengthens the company's financial position but also reflects a strategic shift in leadership aimed at enhancing shareholder value and exploring new opportunities in cancer and viral infection treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDP
Wall Street analysts forecast INDP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.440
Low
10.00
Averages
10.00
High
10.00
Current: 1.440
Low
10.00
Averages
10.00
High
10.00
No data
About INDP
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Indaptus Therapeutics Q1 Financial Analysis
- Financial Performance: Indaptus Therapeutics reported a GAAP EPS of -$0.23 for Q1 2026, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position: As of March 31, 2026, the company had approximately $1.5 million in cash and cash equivalents, a significant decrease from $8.5 million as of December 31, 2025, highlighting liquidity issues that could hinder business growth.
- Capital Raising Needs: The company must raise additional capital to support its business objectives, with no assurance that such financing will be available on acceptable terms, increasing operational uncertainty and potentially impacting strategic execution.
- Strategic Assessment: Indaptus is evaluating financing alternatives and strategic options to support its corporate strategy, and the effectiveness of this process will directly influence the company's long-term development and market competitiveness.
See More
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
- Investment Agreement: Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, issuing 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock, which is expected to bolster the company's capital base and support future strategic developments.
- Leadership Change: David E. Lazar has been appointed Co-CEO and Chairman of the Board, while Jeffrey Meckler will continue as Co-CEO, leading the team to evaluate the company's lead product candidates and explore strategic opportunities aimed at driving shareholder value.
- Board Restructuring: Following the closing of the transaction, the Board was reconstituted with Avraham Ben-Tzvi joining, replacing the resigning Hila Kara and Dr. Robert Martell, reflecting the company's governance adjustments to align with new strategic directions.
- Shareholder Approval: The conversion of shares is contingent upon obtaining shareholder approval at the upcoming meeting expected in Q1 2026, a process that will provide crucial support for the company's future capital structure and shareholder equity.
See More
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
- Investment Agreement Reached: Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, agreeing to issue 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock, thereby strengthening the company's capital base to support future strategic developments.
- Management Changes: Lazar's appointment as Co-CEO and Chairman of the Board reflects the company's confidence in his leadership capabilities, which is expected to drive innovation in cancer and viral infection treatments.
- Shareholder Approval Requirement: The completion of this transaction is contingent upon shareholder approval at the upcoming meeting in Q1 2026, and if approved, Lazar will have the right to nominate up to three new directors, potentially optimizing the board structure further.
- Strategic Opportunity Exploration: Lazar indicated he will actively evaluate the company's lead product candidates while exploring strategic opportunities to enhance shareholder value, demonstrating the company's proactive stance towards transformation and growth.
See More
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
- Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the first half of 2025, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market demand and business expansion capabilities.
- Surge in Stock Price: Following the positive earnings report, the company's shares jumped 59.6% to $0.40 in pre-market trading, reflecting investor confidence in the company's future growth potential.
- Positive Market Reaction: The release of the financial results has significantly increased market attention on Multi Ways Holdings, which is expected to attract more investors to its future developments and strategic plans.
- Strategic Growth Outlook: The robust financial performance not only solidifies the company's position in the industry but also provides ample funding for future expansion and investments, potentially driving further increases in market share.
See More
Indaptus Therapeutics Completes Board Restructuring and Raises $6 Million
- Investor Commitment: Investor David E. Lazar purchased 300,000 shares of Series AA Preferred Stock and 700,000 shares of Series AAA Preferred Stock at $6.00 per share on Monday, generating $6 million in gross proceeds, which will support the company's future initiatives.
- Board Restructuring: Lazar has been appointed as Co-CEO, enhancing leadership stability, while holding derivative securities convertible into 66 million common shares, indicating strong confidence in the company's future prospects.
- Shareholder Vote Scheduled: A special meeting is set for March 31, 2026, to approve the preferred stock conversion and elect new board members, aiming to enhance shareholder engagement and governance structure.
- Market Performance: Despite a market capitalization of $3.47 million and a 92.04% decline in stock price over the past year, Indaptus saw a 64.65% increase in after-hours trading, reflecting positive market sentiment towards the recent financing and management changes.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Indaptus Therapeutics Q1 Financial Analysis
- Financial Performance: Indaptus Therapeutics reported a GAAP EPS of -$0.23 for Q1 2026, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position: As of March 31, 2026, the company had approximately $1.5 million in cash and cash equivalents, a significant decrease from $8.5 million as of December 31, 2025, highlighting liquidity issues that could hinder business growth.
- Capital Raising Needs: The company must raise additional capital to support its business objectives, with no assurance that such financing will be available on acceptable terms, increasing operational uncertainty and potentially impacting strategic execution.
- Strategic Assessment: Indaptus is evaluating financing alternatives and strategic options to support its corporate strategy, and the effectiveness of this process will directly influence the company's long-term development and market competitiveness.
See More
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
- Investment Agreement: Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, issuing 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock, which is expected to bolster the company's capital base and support future strategic developments.
- Leadership Change: David E. Lazar has been appointed Co-CEO and Chairman of the Board, while Jeffrey Meckler will continue as Co-CEO, leading the team to evaluate the company's lead product candidates and explore strategic opportunities aimed at driving shareholder value.
- Board Restructuring: Following the closing of the transaction, the Board was reconstituted with Avraham Ben-Tzvi joining, replacing the resigning Hila Kara and Dr. Robert Martell, reflecting the company's governance adjustments to align with new strategic directions.
- Shareholder Approval: The conversion of shares is contingent upon obtaining shareholder approval at the upcoming meeting expected in Q1 2026, a process that will provide crucial support for the company's future capital structure and shareholder equity.
See More
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
- Investment Agreement Reached: Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, agreeing to issue 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock, thereby strengthening the company's capital base to support future strategic developments.
- Management Changes: Lazar's appointment as Co-CEO and Chairman of the Board reflects the company's confidence in his leadership capabilities, which is expected to drive innovation in cancer and viral infection treatments.
- Shareholder Approval Requirement: The completion of this transaction is contingent upon shareholder approval at the upcoming meeting in Q1 2026, and if approved, Lazar will have the right to nominate up to three new directors, potentially optimizing the board structure further.
- Strategic Opportunity Exploration: Lazar indicated he will actively evaluate the company's lead product candidates while exploring strategic opportunities to enhance shareholder value, demonstrating the company's proactive stance towards transformation and growth.
See More
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
- Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the first half of 2025, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market demand and business expansion capabilities.
- Surge in Stock Price: Following the positive earnings report, the company's shares jumped 59.6% to $0.40 in pre-market trading, reflecting investor confidence in the company's future growth potential.
- Positive Market Reaction: The release of the financial results has significantly increased market attention on Multi Ways Holdings, which is expected to attract more investors to its future developments and strategic plans.
- Strategic Growth Outlook: The robust financial performance not only solidifies the company's position in the industry but also provides ample funding for future expansion and investments, potentially driving further increases in market share.
See More
Indaptus Therapeutics Completes Board Restructuring and Raises $6 Million
- Investor Commitment: Investor David E. Lazar purchased 300,000 shares of Series AA Preferred Stock and 700,000 shares of Series AAA Preferred Stock at $6.00 per share on Monday, generating $6 million in gross proceeds, which will support the company's future initiatives.
- Board Restructuring: Lazar has been appointed as Co-CEO, enhancing leadership stability, while holding derivative securities convertible into 66 million common shares, indicating strong confidence in the company's future prospects.
- Shareholder Vote Scheduled: A special meeting is set for March 31, 2026, to approve the preferred stock conversion and elect new board members, aiming to enhance shareholder engagement and governance structure.
- Market Performance: Despite a market capitalization of $3.47 million and a 92.04% decline in stock price over the past year, Indaptus saw a 64.65% increase in after-hours trading, reflecting positive market sentiment towards the recent financing and management changes.
See More
